leisure time -WSS

leisure time

author：entertainment 2025-09-28 23:29:55 - browse：92

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Diagnostic tests are hitting their mathematical limits

WSS

With clinical trial data readouts, here's how to spot spin

Big Tobacco's 'harm reduction': Is it for real, or a sham?

CDC director unscathed in first congressional testimony

UnitedHealth’s Optum accused of antitrust violations in California

What to do when lifesaving products contribute to climate change

Readout LOUD podcast: Live from STAT Breakthrough Summit West

focus

leisure time

focus

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: Live from STAT Breakthrough Summit West

As demand for Covid shots wanes, Moderna seeks its next success

Organ aging and disease risk measured by new blood test

New air purifier tech could be key to improving indoor air quality

HIV vaccine remains elusive. Immunologists keep trying new ideas

What does generative AI mean for health care? We asked experts

Rep. Raul Ruiz on the physician shortage and more

At least 13 dead in Texas as scorching temps continue

Arc Institute generative AI designs new CRISPR systems

hotspot

BIO selects John Crowley as new CEO

Big Tobacco's 'harm reduction': Is it for real, or a sham?

UnitedHealth’s Optum accused of antitrust violations in California

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Rep. Raul Ruiz on the physician shortage and more

Military medical care influenced by rank and race, new study finds

entertainment

focus

focus

hotspot